Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography

Journal of Biomolecular Screening

Volumn 11, Issue 1, 2006, Pages 13-20

  Yoon, Chi Ho ^a   Kim, Soo Jin ^b   Shin, Beom Soo ^a   Lee, Kang Choon ^a   Yoo, Sun Dong ^a  

^a Sungkyunkwan University   (South Korea)

^b C and C Research Laboratories   (South Korea)

Author keywords

Blood brain barrier; CNS penetration; High throughput screening; Immobilized artificial membrane

Indexed keywords

ACETONITRILE; ALDOSTERONE; ATENOLOL; CAFFEINE; CEFUROXIME; CHLORPROMAZINE; CIMETIDINE; CORTICOSTERONE; DESIPRAMINE; ENALAPRIL; ESTRADIOL; HYDROCORTISONE; IBUPROFEN; IMIPRAMINE; LOMEFLOXACIN; LOPERAMIDE; NADOLOL; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLCHOLINE; PHOSPHODIESTERASE IV INHIBITOR; PIROXICAM; PROGESTERONE; PROMAZINE; PROPRANOLOL; TESTOSTERONE; TIMOLOL;

ARTICLE; ARTIFICIAL MEMBRANE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG PENETRATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PASSIVE TRANSPORT; PH; PREDICTION; PRIORITY JOURNAL; SOLUTE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; BIOLOGICAL ASSAY; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DRUG EVALUATION, PRECLINICAL; HUMANS; MEMBRANES, ARTIFICIAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; STATISTICS; STATISTICS AS TOPIC;

EID: 32844457590     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057105281656     Document Type: Article

References (49)

1. Pardridge WM: CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998 ; 7: 1781-1792.
2. Tamai I, Tsuji A: Transporter-mediated permeation of drugs across the bloodbrain barrier. J Pharm Sci 2000 ; 89: 1371-1388.
3. Clark DE, Pickett S: Computational methods for the prediction of "druglikeness." Drug Discov Today 2000 ; 5: 49-58.
4. Kerns E: High throughput physicochemical profiling for drug discovery. J Pharm Sci 2001 ; 90: 1838-1858.
5. Pardridge WM: Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv Rev 1995 ; 15: 5-36.
6. Young C, Mitchell RC, Brown TH, Ganellin CR, Griffiths R, JonesM,, et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 1988 ; 31: 656-671.
7. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 2. Prediction of blood-brain barrier penetration. J Pharm Sci 1999 ; 88: 815-826.
8. Platts JA, Abraham MH, Zhao YH, Heresy A, Ijaz L, Butina D: Correlation and prediction of a large blood-brain distribution data set: anLFER study. Eur J Med Chem 2001 ; 36: 719-730.
9. Gratton JA, Abraham MH, Bradbury MW, Chadha HS: Molecular factors influencing drug transfer across the blood-brain barrier. J Pharm Pharmacol 1997 ; 49: 1211-1216.
10. Seelig A, Gottschlich R, Devant RM: A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc Natl Acad Sci U S A 1994 ; 91: 68-72.
11. Suomalainen P, Johans C, Söderlund T, Kinnunen PK: Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability. Med Chem 2004 ; 47: 1783-1788.
12. de Lange EC, de Boer BA, Breimer DD: Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 1999 ; 36: 211-227.
13. Mano Y, Higuchi S, Kamimura H: Investigation of the high partition of YM992, a novel antidepressant, in rat brain: in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopharm Drug Dispos 2002 ; 23: 351-360.
14. Shen DD, Artru AA, Adkison KK: Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004 ; 56: 1825-1857.
15. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH: Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004 ; 151: 66-77.
16. Lüdemanm L, Hamm B, Zimmer C: Pharmacokinetic analysis of glioma compartments with dynamicGd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 2000 ; 18: 1201-1214.
17. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ: Evaluation of (R)-[11C]verapamil as PET tracer of Pglycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005 ; 32: 87-93.
18. Siakotos AN, Rouser G, Fleischer S: Isolation of highly purified human and bovine brain endothelial cells and nuclei and their phospholipid composition. Lipids 1969 ; 4: 234-239.
19. Otis KW, Avery ML, Broward-Partin SM, Hansen DK, Behlow HW Jr, Scott DO, et al: Evaluation of the BBMEC model for screening the CNS permeability of drugs. J Pharmacol Toxicol Meth 2001 ; 45: 71-77.
20. Yamazaki M, Terasaki T, Yoshioka K, Nagata O, Kato H, Ito Y,, et al. Carriermediated transport of H1-antagonist at the blood-brain barrier: mepyramine uptake into bovine brain capillary endothelial cells in primarymonolayer cultures. Pharm Res 1994 ; 11: 975-978.
21. Murakami H, Sawada N, Koyabu N, Ohtani H, Sawada Y: Characteristics of choline transport across the blood-brain barrier in mice: correlationwith in vitro data. Pharm Res 2000 ; 17: 1526-1530.
22. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, Pglycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm 2003 ; 263: 113-122.
23. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT: High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003 ; 38: 223-232.
24. Dash AK, Elmquist WF: Separation methods that are capable of revealing blood-brain barrier permeability. J Chromatogr B 2003 ; 797: 241-254.
25. Reichel A, Begley DJ: Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm Res 1998 ; 15: 1270-1274.
26. Sugano K, Hamada H, Machida M, Ushio H: High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 2001 ; 6: 189-196.
27. Ong S, Liu H, Pidgeon C: Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. J Chromatogr A 1996 ; 728: 113-128.
28. Yoon CH, Shin BS, Chang HS, Kwon LS, Kim HY, Yoo SE,, et al. Rapid screening of drug absorption potential using the immobilized artificial membrane phosphatidylcholine column and molar volume. Chromatographia 2004 ; 60: 399-204.
29. Crivori P, Cruciani G, Carrupt P, Testa B: Predicting blood-brain barrier permeation from three-dimensional molecular structure. J Med Chem 2000 ; 43: 2204-2216.
30. Pardridge WM: Transport of protein-bound hormones into tissues in vivo. Endocr Rev 1981 ; 2: 103-123.
31. Bayliss PFC, Duncan ASM: The effects of atenolol (tenormin) and methyldopa on simple tests of central nervous function. Br J Clin Pharmacol 1975 ; 2: 527-531.
32. Jolliet P, Simon N, Bree F, Urien S, Pagliara A, Carrupt PA,, et al. Blood-tobrain transfer of various oxicams: effects of plasma binding on their brain delivery. Pharm Res 1997 ; 14: 650-656.
33. Heykants J, Michiels M, Knaeps A, Brugmans J: Loperamide (R 18 553), a novel type of antidiarrheal agent. Part 5: the pharmacokinetics of loperamide in rats and man. Arzneimittelforschung 1974 ; 24: 1649-1653.
34. Scheld WM: Quinolone therapy for infections of the central nervous system. Rev Infect Dis 1989 ; 11: S1194 - S1202.
35. McCall AL, Millington WR, Wurtman RJ: Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport. Life Sci 1982 ; 31: 2709-2715.
36. Reynolds JEF: Martindale: The Extra Pharmacopoeia. London: Pharmaceutical Press, 1989.
37. Kulkarni SK, Mehta AK, Kunchandy J: Anti-inflammatory actions of clonidine, guanfacine and B-HT 920 against various inflammagen-induced acute paw oedema in rats. Drugs Today 1984 ; 20: 497-507.
38. Tsai TH, Cheng FC, Chen KC, Chen YF, Chen CF: Simultaneous measurement of cefuroxime in rat blood and brain by microdialysis andmicrobore liquid chromatography application of pharmacokinetics. J Chromatogr B 1999 ; 735: 25-31.
39. Dollery C: Therapeutic Drugs. London: Churchill Livingston, 1998.
40. Raevsky OA, Schaper KJ: Quantitative estimation of hydrogen bond contribution to permeability and absorption processes of some chemicals and drugs. Eur J Med Chem 1998 ; 33: 799-807.
41. Yang CY, Cai SJ, Liu H, Pidgeon C: Immobilized artificial membranes: screens for drug-membrane interactions. Adv Drug Deliv Rev 1996 ; 23: 229-256.
42. Rhee D, Markovich R, Chae WG, Qiu X, Pidgeon C: Chromatographic surfaces prepared from lysophosphatidyl choline ligands. Anal Chim Acta 1994 ; 297: 377-386.
43. Xiang TX, Anderson BD: Molecular distributions in interphases: statistical mechanical theory combined with molecular dynamics simulation of a model lipid bilayer. Biophys J 1994 ; 66: 561-573.
44. Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P,, et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J Med Chem 1998 ; 41: 5382-5392.
45. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci 1999 ; 88: 807-814.
46. Zhu C, Jiang L, Chen TM, Hwang KK: A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur J Med Chem 2002 ; 37: 399-407.
47. Kelder J, Grootenhuis PD, Bayda DM, Delbressine LP, Ploemen JP: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of dugs. Pharm Res 1997 ; 16: 1514-1519.
48. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA: Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 1998 ; 6: 151-165.
49. Lennernas H: Dose fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 1997 ; 12: 1573-1582.